Pfizer's Zoetis (ZTS) Sees IPO Price of $22 - $25/Share
Tweet
Share
E-mail
Get Alerts ZTS Hot Sheet
Join SI Premium – FREE
Zoetis Inc. (NYSE: ZTS) filed an amended registration with the U.S. SEC for an Initial Public Offering of its Common Stock. The Company plans to sell 86.1 million shares and sees and offering price of $22 to $25 per share. The Company filed to list on the New York Stock Exchange under the ticker, "ZTS."
Underwriters on the offering are J.P. Morgan, BofA Merrill Lynch, Morgan Stanley, Barclays, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman, Sachs & Co., Guggenheim Securities, Jefferies, BNP PARIBAS, HSBC, Loop Capital Markets, RBC Capital Markets, The Williams Capital Group, L.P., UBS Investment Bank, Lebenthal Capital Markets, Piper Jaffray, and Ramirez & Co., Inc.
Zoetis was an animal health subsidiary of Pfizer Inc. (NYSE: PFE).
Underwriters on the offering are J.P. Morgan, BofA Merrill Lynch, Morgan Stanley, Barclays, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman, Sachs & Co., Guggenheim Securities, Jefferies, BNP PARIBAS, HSBC, Loop Capital Markets, RBC Capital Markets, The Williams Capital Group, L.P., UBS Investment Bank, Lebenthal Capital Markets, Piper Jaffray, and Ramirez & Co., Inc.
Zoetis was an animal health subsidiary of Pfizer Inc. (NYSE: PFE).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Magnolia Oil & Gas launches $1B stock offering for acquisition
- Hancock Whitney gets regulatory approval to acquire One Florida Bank
- Neuronetics names new CFO, promotes executive, and loses legal chief
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, Piper Jaffray, Deutsche Bank, UBS, JPMorgan, Citi, Morgan Stanley, Jefferies & Co, RBC Capital, Barclays, HSBCSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
